Cardiovascular Systems (Cardiovascular Systems) Change In Receivables : $-5.5 Mil (TTM As of Dec. 2022)

View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Change In Receivables?

Cardiovascular Systems's change in receivables for the quarter that ended in Dec. 2022 was $-0.0 Mil. It means Cardiovascular Systems's Accounts Receivable increased by $0.0 Mil from Sep. 2022 to Dec. 2022 .

Cardiovascular Systems's change in receivables for the fiscal year that ended in Jun. 2022 was $0.2 Mil. It means Cardiovascular Systems's Accounts Receivable declined by $0.2 Mil from Jun. 2021 to Jun. 2022 .

Cardiovascular Systems's Accounts Receivable for the quarter that ended in Dec. 2022 was $40.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cardiovascular Systems's Days Sales Outstanding for the three months ended in Dec. 2022 was 59.74.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cardiovascular Systems's liquidation value for the three months ended in Dec. 2022 was $110.7 Mil.

Cardiovascular Systems Change In Receivables Historical Data

The historical data trend for Cardiovascular Systems's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Change In Receivables Chart

Cardiovascular Systems Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Change In Receivables

Get a 7-Day Free Trial

-2.88

-4.92

9.50

-14.82

0.21

Cardiovascular Systems Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Change In Receivables	Get a 7-Day Free Trial															1.51	0.23	-5.11	-0.59	-0.03

Cardiovascular Systems Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.5 Mil.

Cardiovascular Systems (NAS:CSII) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cardiovascular Systems's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	40.232	/	61.453	*	91
=	59.74

2. In Ben Graham's calculation of liquidation value, Cardiovascular Systems's accounts receivable are only considered to be worth 75% of book value:

Cardiovascular Systems's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	132.002	-	72.117	+	0.75 * 40.232	+	0.5 * 41.191
=	110.7

Cardiovascular Systems Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiovascular Systems (Cardiovascular Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416

Website

https://www.csi360.com

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.

Executives

Jeffrey S. Points	officer: Chief Financial Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward	director	RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb	officer: Chief Operating Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson	director	40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein	officer: General Counsel & Corp. Secy	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo	officer: Chief Compliance Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe	officer: Chief Human Resources Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings	officer: VP Manufacturing & Operations	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland	officer: VP of Medical Affairs	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver	officer: VP of Corp. Dev. & IP	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund	officer: Chief Talent Officer